Middle East and Africa Cardiometabolic Diseases Market

Market Introduction

The cardiometabolic disease is characterized by a group of abnormalities and symptoms that raise the risk of individuals developing cardiovascular disease. Hypertension, obesity, insulin resistance, dyslipidemia, poor cholesterol profile (LDL), and glucose tolerance are some of the symptoms. Individuals suffering from cardiometabolic syndrome are prone to several other life-threatening diseases such as type 2 diabetes, stroke, coronary artery disease (CAD), cardiovascular disease (CVD), and many others.

Moreover, the increasing prevalence of cardiometabolic diseases is expected to bolster the market growth during the forecast period. However, underdiagnosis of CVDs in low- and middle-income countries (LMICs) limits the growth of the Middle East and Africa cardiometabolic diseases market.

The pandemic has increased the demand for medical devices that can be used in a home care setting. The region has observed increasing numbers of patients admitted to intensive care units (ICU). A rising number of medications imposing multiple diagnostic and therapeutic challenges on stressed healthcare systems, leading to a rise in medical devices and pharmaceuticals. Also, the increasing number of cases of chronic conditions has increased, which resulted in an increased use of drugs for combating the virus. During the widespread COVID-19 pandemic, there have been worries about the potential of certain blood pressure medications such as angiotensin converting enzyme inhibitors (ACEi) and angiotensin-converting blockers (ARB). The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses the membrane-bound angiotensin-converting enzyme 2 (ACE2) receptors to facilitate entry into the host cell. This pandemic enhanced the business operation of the various drug manufacturers operating in the cardiometabolic diseases market in the region.

Market Overview and Dynamics

The Middle East and Africa cardiometabolic diseases market is projected to reach US$ 5,008.5 million by 2028 from US$ 4,300.9 million in 2021; it is anticipated to grow at a CAGR of 2.2% from 2021 to 2028. CMD-based drug candidate pipeline is expanding for a wide range of therapeutic applications, including hypertension, diabetes, and inflammatory disorders. Many big and small pharmaceutical companies are involved in developing several small-molecule drugs. For instance, AstraZeneca has more than 25 therapies and therapy combinations in its early-to-late-stage cardiovascular, renal, and metabolism (CVRM). Based on advanced technologies, several products are being introduced for the treatment of CMDs. Further, the increasing investment in research related to CMDs is propelling the cardiometabolic diseases market significantly. All these investments are reflected positively on this Middle East and Africa cardiometabolic diseases market’s growth.

Key Market Segments

In terms of type, the cardiovascular disease segment accounted for the largest share of the Middle East and Africa cardiometabolic diseases market in 2020. In terms of treatment, the ACE inhibitors segment accounted for the largest share of the Middle East and Africa cardiometabolic diseases market in 2020. In terms of dosage, the tablet segment accounted for the largest share of the Middle East and Africa cardiometabolic diseases market in 2020. In terms of route of administration, the oral segment accounted for the largest share of the Middle East and Africa cardiometabolic diseases market in 2020. In terms of end user, the hospital segment accounted for the largest share of the Middle East and Africa cardiometabolic diseases market in 2020. Further, based on distribution channel, the hospital pharmacy segment held the largest market share in 2020.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the cardiometabolic diseases market in Middle East and Africa are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Bayer AG, Novartis AG, Boehringer Ingelheim International Gmbh, Novo Nordisk A/S, and AstraZeneca.

Reasons to Buy Report

• To understand the Middle East and Africa cardiometabolic diseases market landscape and identify market segments that are likely to guarantee a strong return
• To comprehend the ever-changing market landscape and stay ahead in competition
• To efficiently plan merger and acquisition, and partnership deals in the Middle East and Africa cardiometabolic diseases market by identifying segments with the most promising probable sales
• To make knowledgeable business decisions from perceptive and comprehensive analysis of the market performance of various segments
• To obtain market revenue forecast of the Middle East and Africa cardiometabolic diseases market based on various segments for the period 2021–2028

MIDDLE EAST AND AFRICA CARDIOMETABOLIC DISEASES MARKET SEGMENTATION

By Type

• Cardiovascular disease (CVD)
• Type 2 diabetes
• Hypertension
• Obesity 

By Treatment

• ACE inhibitors
• Diuretics
• Glucophage
• Others 

By Dosage

• Tablet
• Injection 

By Route of Administration

• Oral
• Intravenous 

By End Users

• Hospital
• Clinic
• Homecare settings 

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Country

• Middle East and Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East and Africa

Companies Mentioned

• Bayer AG                         
• Novartis AG                   
• Boehringer Ingelheim International Gmbh
• Novo Nordisk A/S       
• AstraZeneca                  

Middle East and Africa Cardiometabolic Diseases Market Strategic Insights

Middle East and Africa Cardiometabolic DiseasesMarket Report Highlights

Middle East and Africa Cardiometabolic Diseases Market Country and Regional Insights